VRXA surges on Nasdaq debut after SPAC merger close with low float

 

VRXA surges 67% on Nasdaq debut after SPAC merger close with low float

• VERAXA Biotech's business combination with Voyager Acquisition Corp (VACH) closed around June 8-10, 2026.
• June 10 press release announced trading under VRXA (and VRXAW warrants) would begin June 11.
• Extremely high SPAC redemptions (~99.67%) resulted in very low public float, amplifying volatility on first trading day.
• Biotech hype around VERAXA's novel BiTAC platform for bispecific T-cell engagers and antibody-drug conjugates for cancer added retail interest.
• Multiple trading halts reported as stock ran sharply higher on momentum and low share supply.
• Typical pattern for low-float de-SPAC/redemption plays driving outsized first-day gains without new clinical data.

https://finviz.com/stock?t=VRXA&p=d